Sugi Predict

Sugi Predict / Compounds / SCHEMBL289652

SCHEMBL289652

SCHEMBL289652

OB(O)c1ccc2sccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CYP2A6 P11509 2/20 0.46
▸ DYRK1A Q13627 1/20 0.42
▸ PTPRC P08575 1/20 0.41
▸ PTPN6 P29350 1/20 0.41
▸ PTPN11 Q06124 1/20 0.41
▸ PTPN22 Q9Y2R2 1/20 0.41
▸ CTNNB1 P35222 1/20 0.40
▸ WNT3A P56704 1/20 0.40
▸ ENPP2 Q13822 3/20 0.37
▸ CA12 O43570 3/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31724842 0.83 CA1 (0.47) CA2CA1CYP2A6ENPP2
SCHEMBL2562351 0.83 CA1 (0.47) CA2CA1CYP2A6ENPP2
SCHEMBL6606924 0.72 PTPRC (0.35) CA2CYP2A6DYRK1APTPRCPTPN6
SCHEMBL31354846 0.71 CA2 (0.80) CA2CA1ENPP2KDM4EALDH1A1
SCHEMBL205203 0.71 CA2 (0.80) CA2CA1ENPP2KDM4EALDH1A1
SCHEMBL30656341 0.71 CYP2A6 (0.50) CA2CYP2A6DYRK1APTPRCPTPN6
SCHEMBL534539 0.71 CYP2A6 (0.50) CA2CYP2A6DYRK1APTPRCPTPN6
SCHEMBL30611497 0.71 CA2 (0.42) CA2CA1CYP2A6ENPP2KDM4E
SCHEMBL929430 0.70 CYP2A6 (0.48) CA2CYP2A6DYRK1APTPRCPTPN6
SCHEMBL17011001 0.70 CYP2A6 (0.48) CA2CYP2A6DYRK1APTPRCPTPN6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025046419-A1 NOVEL COMPOUND AS NLRP3 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 제일약품주식회사 2025-03-06 — — WO disclosed
CN-118047793-A Pyridine derivative and application thereof 成都百裕制药股份有限公司 2024-05-17 — — CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
CN-110938065-A Heterocycle modified carbazole-triazine derivative, preparation method and application thereof 苏州大学 2020-03-31 — — CN disclosed
US-10351552-B2 Bicyclic antiparasitic compounds MediSynergies, LLC (US) 2019-07-16 — — US disclosed
US-20190177304-A1 Bicyclic Antiparasitic Compounds MediSynergics, LLC (US) 2019-06-13 — — US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 — — US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 — — US disclosed
US-20150344503-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME INFINITY PHARMACEUTICALS INC (US) 2015-12-03 — — US disclosed
US-20150344503-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME INFINITY PHARMACEUTICALS INC (US) 2015-12-03 — — US disclosed
EP-1863802-A1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS Speedel Experimenta AG (CH) 2007-12-12 — — EP disclosed
EP-1814872-A1 SUBSTITUTED [(PHENYLETHANOYL)AMINO] BENZAMIDES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AND CARDIO-VASCULAR DISEASES Bayer HealthCare AG (DE) 2007-08-08 — — EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 — — US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 — — US disclosed
CN-1856498-A Thienopyridine and furopyridine kinase inhibitors ABBOTT LAB (US) 2006-11-01 — — CN disclosed
WO-2006103273-A1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2006-10-05 — — WO disclosed
WO-2006053748-A1 SUBSTITUTED [(PHENYLETHANOYL)AMINO] BENZAMIDES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AND CARDIO-VASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2006-05-26 — — WO disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 — — EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 — — US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351552-B2 Bicyclic antiparasitic compounds TBCA, NAT1, HDAC1 CA2 1785/4885CA1 2528/4885CYP2A6 1358/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA2 1487/4885CA1 822/4885CYP2A6 94/4885
US-20150344503-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME FAAH, FAAH2, ASAH1 CA2 1188/4885CA1 821/4885CYP2A6 175/4885
US-20190177304-A1 Bicyclic Antiparasitic Compounds TBCA, NAT1, HDAC1 CA2 1785/4885CA1 2528/4885CYP2A6 1358/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK CA2 1789/4885CA1 4643/4885CYP2A6 3411/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK CA2 1789/4885CA1 4643/4885CYP2A6 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.